



**PATENT**  
Attorney Docket No. PRMG-06684

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: John W. Shultz *et al.*

Serial No.: 09/995,912

Filed: 11/28/01

Entitled: RNA Polymers And Uses Thereof

Group No.: 1634

Examiner: A. Chakrabarti

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: July 7, 2003

By: Susan M. McClintock  
Susan McClintock

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any fee or credit overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: July 7, 2003

David A. Casimir  
David A. Casimir  
Registration No. 42,395

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: John W. Shultz *et al.*

Serial No.: 09/995,912

Filed: 11/28/01

Entitled: **RNA Polymers And Uses Thereof**

Group No.: 1634

Examiner: A. Charkrabarti

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: July 7, 2003

By:

*Susan M. McClintock*  
Susan McClintock

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following references were cited in the previous Information Disclosure Statement, but copies were not provided at that time:


- 1) Badet et al., PNAS, 86:8427 (1989)
- 2) Wetmur, Crit. Rev. Biochem. and Mol. Biol. 26:227 (1991)
- 3) Delcardayre et al., Protein Engineering, 8:261 (1995)
- 4) Rahman et al., Anal. Chem., 68:134 (1996)
- 5) Shimoyama et al., Clin. Cancer Res. 5:1125 (1999)

The following references were cited in an office action in a related application:

- 1) GIBCO BRL Catalogue & Reference Guide, AME Reverse Transcriptase System, page 376.
- 2) Sambrook et al., Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989, pp 7.3-7.4.
- 3) Preddie, J. Biol. Chem., 244(14), 3969 (1969)
- 4) Promega Corporation, Product Bulletin, M-MLV Reverse Transcriptase
- 5) Sarngadharan et al., J. Virology, 27(3), 568 (1978)
- 6) Tewari and Burma, Biochem. Biophys. Res. Comm., 109(1), 256 (1982)
- 7) Venkov et al., J. Bacteriology, 108(1), 601 (1971)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: July 7, 2003

  
\_\_\_\_\_  
David A. Casimir  
Registration No. 42,395  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 305  
San Francisco, California 94105  
608/218-6900

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: PRMG-06684

Serial No.: 09/995,912

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use Several Sheets If Necessary)Applicant: John W. Shultz *et al.*

(37 CFR § 1.98(b))

Filing Date: 11/28/01

Group Art Unit: 1634

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date

**FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS**

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

/	1	Badet et al., PNAS, 86:8427 (1989)
/	2	Wetmur, Crit. Rev. Biochem. and Mol. Biol. 26:227 (1991)
✓	3	Delcardayre et al., Protein Engineering, 8:261 (1995)
✓	4	Rahman et al., Anal. Chem., 68:134 (1996)
/	5	Shimoyama et al., Clin. Cancer Res. 5:1125 (1999)
✓	6	GIBCO BRL Catalogue & Reference Guide, AME Reverse Transcriptase System, page 376
/	7	Sambrook et al., Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989, pp 7.3-7.4.
/	8	Preddie, J. Biol. Chem., 244(14), 3969 (1969)
	4	Promega Corporation, Product Bulletin, M-MLV Reverse Transcriptase
	10	Samgadharan et al., J. Virology, 27(3), 568 (1978)
	10	Tewari and Burma, Biochem. Biophys. Res. Comm., 109(1), 256 (1982)
	10	Venkov et al., J. Bacteriology, 108(1), 601 (1971)
	13	
	14	
	15	
	16	
	17	
	18	

Examiner:

Date Considered:

**EXAMINER:**

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.